| Column1 | Study Population | Sample Size at Risk of Recurrence | HPV Detection | Age | Mean Follow-Up | Sampling Interval | Incidence or Proportion of Recurrent Detection | Cumulative Proportion with New Partner | Recurrence Associated with New Partner? |
|---|---|---|---|---|---|---|---|---|---|
| Trottier, et al. Cancer Res 2010; 70 [21] | Ludwig-McGill Cohort Study, Brazil | 566 | MY09/11 PCR; 38 types | mean 32.7 (18.59) | 59.0 months | Y1: every 4 months Y2+: every 6 months | all types 1.5 (0.9-2.3) per 1000 woman-mo | 19.3% | 3.7 (1.1-13.8)a |
| Insinga, et al. CEBP 2010; 19 [6] | Placebo arm of Merck Protocol V501-012 Gardasil trial | 827 | Merck PCR; 9 types | 16-23 | up to 48 months | every 6 months | 8.2% (est from Table 4) | 16.3% | Not significant, no estimate reported |
| Rodriguez, et al. Int J Cancer 2011 Epub ahead of print doi: 10.1002/ijc.27418 | Guancaste Cohort Study, Costa Rica | 1052 | MY09/11 PCR; 50 types | range 18-84 | 7.01 years (IQR 6.95-7.05) | yearly or semi-annually | 7.7% | not reported | 7/81 (8.6%) of reappearing infections occurred in women reporting a new sex partner |
| Winer, et al. CEBP 2011; 20 [4] | University of Washington students | 173 | PGMY09/11 PCR; 37 HPV types | 19.2 (SD 1.5) | 24.3 months (SD 15.7) | every 4 months | 19.4% | not reported | not reported |